Down‐regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized phenotypically by memory impairment, histologically by accumulation of pTau and β‐amyloid peptide and morphologically by a loss of nerve terminals in cortical and hippocampal regions. As glutamate is the principle excitatory neurotransmitter of the central nervous system (CNS), the glutamatergic system may play an important role in AD. To date, not many studies have addressed the deleterious effects of Aβ on glutamatergic terminals; therefore the aim of this study was to investigate how Aβ affects glutamatergic terminals and to assess the extent to which alterations in the glutamatergic neurotransmission could impact susceptibility to the illness. The present study shows that Aβ caused a loss of glutamatergic terminals, measured by VGLUT1 protein levels, in Tg2576 primary cell cultures, Tg2576 mice and AD patient brains, and also when Aβ was added exogenously to hippocampal cell cultures. Interestingly, no correlation was found between cognition and decreased VGLUT1 levels. Moreover, when Aβ 1–42 was intracerebroventricularlly administered into VGLUT1+/‐ mice, altered synaptic plasticity and increased neuroinflammation was observed in the hippocampus of those animals. In conclusion, the present study not only revealed susceptibility of glutamatergic nerve terminals to Aβ induced toxicity but also underlined the importance of VGLUT1 in the progression of AD, as the decrease of this protein levels could increase the susceptibility to subsequent deleterious inputs by exacerbating Aβ induced neuroinflammation and synaptic plasticity disruption. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“, 2000), which is also found in different animal models of AD (Mucke et al., 2000; Jacobsen et al., 2006; Canas et al., 2009).”
BackgroundPalop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653 · cited 1×
“, 2009), suggesting that plaques can alter the functionality of neuronal synapses (Palop et al., 2007; Rudinskiy et al., 2012).”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“In this line, the exposure to Ab is correlated (N€aslund et al., 2000; Fagan et al., 2007) and induces memory impairment (reviewed in Selkoe, 2008) and the intracerebroventricular (icv) administration of Ab is nowadays a stablished model of experimental AD (Lawlor and Young, 2010).”
BackgroundInflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
AMPAR Removal Underlies Aβ-Induced Synaptic Depression and Dendritic Spine Loss
Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S., & Malinow, R. (2006) · Neuron · doi:10.1016/j.neuron.2006.10.035 · Cited by 1,042
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017 · cited 2×
“Indeed, synapse loss has been reported to occur very early in AD-affected brain regions such as frontal or temporal cortex and correlates closely with cognitive decline (Terry et al., 1991; Scheff et al., 2006).”
BackgroundSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Takamori, S., Rhee, J. S., Rosenmund, C., & Jahn, R. (2000) · Nature · doi:10.1038/35025070 · Cited by 862
Research works printed but not linked: 34
- 10.1523/JNEUROSCI.1856-09.2009 · DOI · Paper page
- 10.1016/j.ejphar.2006.06.045 · DOI
- 10.1523/JNEUROSCI.3269-07.2007 · DOI · Paper page
- 10.1126/science.289.5481.957 · DOI · Paper page
- 10.1523/JNEUROSCI.3728-09.2009 · DOI · Paper page
- 10.1016/j.neuropharm.2013.08.026 · DOI
- 10.1016/j.neurobiolaging.2011.09.021 · DOI
- 10.1016/S0301-0082(00)00067-8 · DOI · Paper page
- 10.1016/j.neuron.2007.09.001 · DOI · Paper page
- 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- 10.1016/j.biopsych.2009.02.027 · DOI
- 10.1126/science.1072994 · DOI · Paper page
- 10.1111/j.1471-4159.2006.04144.x · DOI · Paper page
- 10.1126/science.274.5284.99 · DOI · Paper page
- 10.3233/JAD-2003-5106 · DOI · Paper page
- 10.1016/j.neurobiolaging.2007.04.010 · DOI · Paper page
- 10.1111/j.1471-4159.2006.03935.x · DOI · Paper page
- 10.1212/WNL.0b013e3181fd6328 · DOI
- 10.1212/WNL.57.5.805 · DOI · Paper page
- Lawlor PA, 2010, Animal Models of Dementia, 347
- 10.1016/S0893-133X(01)00393-1 · DOI · Paper page
- 10.1006/exnr.2000.7386 · DOI
- 10.1101/lm.69204 · DOI · Paper page
- 10.1111/j.1471-4159.2007.05147.x · DOI · Paper page
- 10.1038/cddis.2015.72 · DOI · Paper page
- 10.1016/S0896-6273(03)00434-3 · DOI · Paper page
- 10.3233/JAD-2010-100090 · DOI · Paper page
- 10.1016/j.bbadis.2016.01.004 · DOI
- 10.1016/j.nbd.2011.08.027 · DOI · Paper page
- 10.1016/S0022-510X(00)00285-9 · DOI · Paper page
- 10.1002/ana.410300410 · DOI · Paper page
- 10.3233/JAD-130437 · DOI
- 10.1111/j.1460-9568.2006.05259.x · DOI · Paper page
- 10.1523/JNEUROSCI.4391-04.2005 · DOI · Paper page
Cited by
Wingo, A. P., Dammer, E. B., Breen, M. S., Logsdon, B. A., Duong, D. M., Troncosco, J. C., Thambisetty, M., Beach, T. G., Serrano, G. E., Reiman, E. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09613-z · Cited by 211
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
Guo, Q., Li, Y., Xu, S., Wang, P., Qian, K., Yang, P., Sheng, D., Wang, L., Cheng, Y., Meng, R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.074 · Cited by 40
Guo, Q., Wang, T., Qian, C., & Wang, X. (2024) · Small · doi:10.1002/smll.202403980 · Cited by 15
Metadata
- Authors
- Rodriguez‐Perdigon, M., Tordera, R. M., Gil‐Bea, F. J., Gerenu, G., Ramirez, M. J., & Solas, M.
- Venue
- Hippocampus
- Publisher
- Wiley
- Published
- 2016-06-21
- Volume
- 26
- Issue
- 10
- Pages
- 1303-1312
- ISSN
- 1050-9631 (ISSN-L)
- 1098-1063
- OpenAlex
- W2414111041
- Cited by
- 47
- References
- 20
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Instituto de Salud Carlos III (FIS 13/00858)
- Federación Española de Enfermedades Raras
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.